This technique aims to block the overexpressing programmed cell death-1 (PD-1) in T cells and programmed cell death ligand-1 (PD-L1) in cancer cells, with the cytotoxic T lymphocyte antigen-4 (CTLA-4) protein receptors acting as checkpoints for cancer treatment. Here, CTLA4 is linked to cancer.